Sugi Predict

Sugi Predict / Compounds / SCHEMBL2264244

SCHEMBL2264244

SCHEMBL2264244

C[C@@](N)([C]=O)Cc1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 3/20 0.62
▸ SLC6A2 P23975 3/20 0.62
▸ SLC6A3 Q01959 2/20 0.62
▸ HTR2A P28223 1/20 0.62
▸ HRH1 P35367 1/20 0.62
▸ HTR2B P41595 1/20 0.62
▸ CHRNA4 P43681 1/20 0.62
▸ CYP3A4 P08684 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ NLRP3 Q96P20 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ TAAR1 Q96RJ0 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8179261 1.00 SLC6A4 (0.62) SLC6A4SLC6A2SLC6A3HTR2AHRH1
SCHEMBL5057766 0.81 BLM (0.58) SLC6A4SLC6A2SLC6A3HTR2AHRH1
SCHEMBL8581415 0.81 BLM (0.58) SLC6A4SLC6A2SLC6A3HTR2AHRH1
SCHEMBL1085634 0.81 BLM (0.58) SLC6A4SLC6A2SLC6A3HTR2AHRH1
SCHEMBL1085975 0.80 SLC6A2 (0.59) SLC6A4SLC6A2SLC6A3HTR2AHRH1
SCHEMBL9529208 0.80 SLC6A4 (0.55) SLC6A4SLC6A2SLC6A3HTR2AHRH1
SCHEMBL1085977 0.80 SLC6A2 (0.59) SLC6A4SLC6A2SLC6A3HTR2AHRH1
SCHEMBL2265345 0.80 SLC6A2 (0.59) SLC6A4SLC6A2SLC6A3HTR2AHRH1
Chlorphentermine SCHEMBL160516 0.77 SLC6A2 (1.00) SLC6A4SLC6A2SLC6A3HTR2AHRH1
SCHEMBL28848601 0.77 SLC6A4 (0.67) SLC6A4SLC6A2SLC6A3HTR2AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195898-A1 TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS VOYAGER PHARMACEUTICAL CORPORATION (US) 2011-08-11 — — US claimed
US-20080171736-A1 Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists VOYAGER PHARMACEUTICAL CORPORATION 2008-07-17 — — US claimed
US-5767082-A ANTIFERTILITY AGENTS SYNTEX (U.S.A.) INC. (US) 1998-06-16 — — US claimed
EP-0277829-B1 Nonapeptide and decapeptide analogs of LHRH as LHRH antagonists SYNTEX INC (US) 1994-07-27 — — EP claimed
EP-0400065-A4 LHRH ANALOGS — 1991-03-13 — — EP claimed
EP-0413209-A1 LHRH analogs TAP Pharmaceuticals Inc. (US) 1991-02-20 — — EP claimed
EP-0400065-A1 LHRH ANALOGS. ABBOTT LAB (US) 1990-12-05 — — EP claimed
WO-1989007450-A1 LHRH ANALOGS ABBOTT LABORATORIES (US) 1989-08-24 — — WO claimed
EP-0328090-A2 LHRH analogs ABBOTT LABORATORIES (US) 1989-08-16 — — EP claimed
EP-0301850-A2 LHRH antagonist analogs and 19-nor-progestational steroids for therapy SYNTEX (U.S.A.) INC. (US) 1989-02-01 — — EP claimed
EP-0277829-A2 Nonapeptide and decapeptide analogs of LHRH as LHRH antagonists SYNTEX (U.S.A.) INC. (US) 1988-08-10 — — EP claimed
US-20110195898-A1 TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS VOYAGER PHARMACEUTICAL CORPORATION (US) 2011-08-11 — — US disclosed
US-20080171736-A1 Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists VOYAGER PHARMACEUTICAL CORPORATION 2008-07-17 — — US disclosed
US-6156731-A Polypeptide composition for oral administration G. D. SEARLE & CO. (US) 2000-12-05 — — US disclosed
US-5767082-A ANTIFERTILITY AGENTS SYNTEX (U.S.A.) INC. (US) 1998-06-16 — — US disclosed
EP-0328090-A2 LHRH analogs ABBOTT LABORATORIES (US) 1989-08-16 — — EP disclosed
EP-0312052-A1 Intranasal administration of polypeptides in powdered form SYNTEX (U.S.A.) INC. (US) 1989-04-19 — — EP disclosed
EP-0301850-A2 LHRH antagonist analogs and 19-nor-progestational steroids for therapy SYNTEX (U.S.A.) INC. (US) 1989-02-01 — — EP disclosed
US-4801577-A REPRODUCTION CONTROL SYNTEX (U.S.A.) INC. (US) 1989-01-31 — — US disclosed
EP-0277829-A2 Nonapeptide and decapeptide analogs of LHRH as LHRH antagonists SYNTEX (U.S.A.) INC. (US) 1988-08-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195898-A1 TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS GNRHR, GRIN1, GRIN3A SLC6A4 1207/4885SLC6A2 1034/4885SLC6A3 878/4885
US-20080171736-A1 Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists GNRHR, GRIN1, GRIN3A SLC6A4 1207/4885SLC6A2 1034/4885SLC6A3 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.